Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis

Thibodeaux, Quinn; Ly, Karen; Reddy, Vidhatha; Smith, Mary Patricia; Liao, Wilson

doi:10.1016/j.jdcr.2019.08.015

Cited by 22 publications

(19 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite safety concerns in combining two biological drugs, few reports of serious side effects emerge from the current literature (Table 1 ). 26 , 27 , 28 , 29 , 30 , 31 , 32 When considering a dual biological therapy, it is mandatory to weigh all risk and benefits for the patient and collaborate with other specialists in choosing the association for the management of the comorbidity.…”

Section: Resultsmentioning

confidence: 99%

Latest combination therapies in psoriasis: Narrative review of the literature

Diotallevi

Paolinelli

Radi

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always provide complete control of the disease or associated comorbidities over time. The first biological drugs used for the treatment of psoriasis, tumor necrosis factor alpha inhibitors, have

show abstract

Section: Resultsmentioning

confidence: 99%

Latest combination therapies in psoriasis: Narrative review of the literature

Diotallevi

Paolinelli

Radi

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…While there are case reports of dual biologic therapy potentially causing adverse events, there have also been cases reported where dual biologic therapy was well tolerated and significantly helped patients’ symptoms. 4 -7…”

Section: Discussionmentioning

confidence: 99%

A Review of Drug-Drug Interactions for Biologic Drugs Used in the Treatment of Psoriasis

Armanious

Vender

2020

J Cutan Med Surg

View full text Add to dashboard Cite

Biologic drugs are increasingly being prescribed for the treatment of psoriasis. Very little information is available in the literature regarding potential drug interactions with these medications. This paper serves as a guide for prescribers to be aware of possible interactions between biologic drugs approved for the treatment of psoriasis in North America and concomitant therapies. Objective To provide an overview of reported drug interactions between biologic drugs and concomitant therapies. Methods Reports of potential drug interactions were compiled through a search of Micromedex, drug monographs (Canadian, American, and European), as well as a PubMed search of each biologic drug with the term “drug interaction.” Conclusion Generally, caution should be exercised when multiple immunosuppressive therapies are prescribed due to increased risk of infection. However, this is more the result of a synergistic effect as opposed to a true drug interaction. There have been cases where multiple biologic therapies have been concomitantly used without adverse events, as their mechanisms involved different pathways. The sources used to compile this guide were often comprised of low levels of evidence, reinforcing the idea that further studies are required to better direct prescribers.

show abstract

“…The experience with this compound illustrates how a dual immunomodulatory strategy can concomitantly improve clinically relevant synovio–entheseal (e.g., ACR70) and skin (e.g., PASI90) outcomes in PsA patients without increased risk of infection. A variety of case reports have described significant clinical improvement with simultaneous use of TNFi and ustekinumab or guselkumab in 15 patients with recalcitrant PsA that was nonresponsive to multiple biologic disease‐modifying antirheumatic drug (DMARD) monotherapy regimens (20). However, these patients had chronic, advanced disease and almost half of them developed infections.…”

Section: The Challenge: a Path To Remission In Psoriatic Arthritismentioning

confidence: 99%